Impact News +++ EXPD Tops Q4 Earnings & Revenue Estimates, Announces Buyback Program (Zacks) +++ EXPEDITORS INTL Aktie -3,45%

AB SCIENCE Aktie

>AB SCIENCE Aktienkurs

1.4 EUR +5.3% (TradegateBSX)

Ask: 1.43 EUR / 350 Stück

Bid: 1.4 EUR / 350 Stück

Tagesumsatz: 1867 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

AB SCIENCE Aktie über LYNX handeln

Intraday

1 Jahr

>AB SCIENCE Performance

1 Woche: +2,5%

1 Monat: -7,7%

3 Monate: +14,2%

6 Monate: +1,4%

1 Jahr: -2,8%

laufendes Jahr: -4,8%

>AB SCIENCE Aktie

Name:

AB SCIENCE S.A. EO-,01

Land:

Frankreich

Sektor:

Gesundheit

ISIN/ Wkn:

FR0010557264 / A1CXBG

Symbol/ Ticker:

A8D (Frankfurt)

Kürzel:

FRA:A8D, ETR:A8D, A8D:GR

Index:

Webseite:

https://www.ab-science.co..

Profil:

AB Science S.A. is a clinical-stage pharmaceutical company headquartered in Paris, France, founded in 2001. It specializes in the research, design, development, and marketing of innovative drugs targe..
>Volltext..

Marktkapitalisierung:

88.45 Mio. EUR

Unternehmenswert:

102.45 Mio. EUR

Umsatz:

1.03 Mio. EUR

EBITDA:

-6.85 Mio. EUR

Nettogewinn:

-8.54 Mio. EUR

Gewinn je Aktie:

-0.15 EUR

Schulden:

19.04 Mio. EUR

Liquide Mittel:

5.03 Mio. EUR

Operativer Cashflow:

-6.88 Mio. EUR

Bargeldquote:

0.27

Umsatzwachstum:

-5.08%

Gewinnwachstum:

-107.96%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

AB SCIENCE

Letzte Datenerhebung:

24.02.26

>AB SCIENCE Kennzahlen

Aktien/ Unternehmen:

Aktien: 66.18 Mio. St.

Frei handelbar: 89.59%

Leerverk. Aktien: -

Rückkaufquote: -5.42%

Mitarbeiter: 39

Umsatz/Mitarb.: 0.02 Mio. EUR

Analysten:

Analystenrating: Strong buy

Kursziel: 90.41%

Bewertung:

KGV: -

KGV lG: -

KUV: 79.51

KBV: -

PEG-Ratio: -0.11

EV/EBITDA: -

Rentabilität:

Bruttomarge: 18.7%

Gewinnmarge: -831.45%

Operative Marge: -739.53%

Managementeffizenz:

Gesamtkaprendite: -38.64%

Eigenkaprendite: -

>AB SCIENCE Peer Group

Gesundheit, Onkologie/ Krebs- Behandlung

>AB SCIENCE Chart & Kurs - Tradegate

>AB SCIENCE News

24.02.26 - 18:06	AB Science announces the identification of a plasma biomarker that indicates the activity of masitinib in treating ALS (GlobeNewswire EN)
	PRESS RELEASE...

10.02.26 - 16:06	Reportable, Inc.: Stonegate Capital Partners Initiates Coverage on AB Science S.A. (AB) (Newsfile)
	Dallas, Texas--(Newsfile Corp. - February 10, 2026) - AB Science S.A. (ENXTPA: AB): Stonegate Capital Partners Initiates Coverage on AB Science S.A. (ENXTPA: AB). AB Science is a late-stage biotec......

09.02.26 - 18:09	AB Science announced that the Food and Drug Administration (FDA) granted the status of Minor Use in Major Species (MUMS) for Masivet® in the treatment of canine mast cell tumors (GlobeNewswire EN)
	PRESS RELEASE...

29.01.26 - 18:03	AB Science receives notice of allowance for US patent covering masitinib in the treatment of metastatic castrate resistant prostate cancer (GlobeNewswire EN)
	PRESS RELEASE...

21.01.26 - 18:06	AB Science receives Japanese patent protection for the use of masitinib in progressive forms of multiple sclerosis (MS) until 2041 (GlobeNewswire EN)
	PRESS RELEASE...

07.01.26 - 18:06	AB Science reports fourth consecutive case of response from Phase 1 data for the combination of AB8939 with venetoclax for the treatment of refractory or relapsed acute myeloid leukemia (GlobeNewswire EN)
	PRESS RELEASE...

22.12.25 - 18:00	AB Science patent for masitinib in the treatment of sickle cell disease formally granted in the US with a protection until 2040 (GlobeNewswire EN)
	PRESS RELEASE...

18.12.25 - 19:21	AB Science announces the initiation of coverage of its stock by Maxim Group with a target price of EUR 4.0 per share (GlobeNewswire EN)
	PRESS RELEASE...

15.12.25 - 18:42	AB Science announces a new publication on biorxiv that identifies AB8939 as a promising drug candidate for treating refractory acute myeloid leukemia and potentially other cancers (GlobeNewswire EN)
	PRESS RELEASE...

11.12.25 - 18:33	AB Science announces new publication on Medrxiv highlighting clinical benefit with masitinib in Amyotrophic Lateral Sclerosis patients prior any complete loss of function (GlobeNewswire EN)
	PRESS RELEASE...

17.10.25 - 08:03	AB Science announces the successful completion of a EUR 2.8 million private placement (GlobeNewswire EN)
	PRESS RELEASE...

16.10.25 - 21:00	AB Science provides intitial Phase 1 data for the combination of AB8939 with venetoclax for the treatment of refractory or relapsed acute myeloid leukemia (GlobeNewswire EN)
	PRESS RELEASE...

14.10.25 - 08:39	AB Science will hold a virtual conference on Thursday, October 16, 2025 from 2pm to 3pm CET to provide an update on the Phase 1 study with AB8939 (GlobeNewswire EN)
	PRESS RELEASE...

10.10.25 - 18:12	AB Science today reports its revenues for the first half of 2025 and provides an update on its activities (GlobeNewswire EN)
	PRESS RELEASE...

30.09.25 - 18:36	AB Science announces a slight delay in the publication of its 2025 half-year financial report (GlobeNewswire EN)
	PRESS RELEASE...

04.08.25 - 08:00	AB Science announces the successful completion of a 2.55 million euros private placement (GlobeNewswire EN)
	PRESS RELEASE...

30.07.25 - 07:48	AB Science receives regulatory approval from European countries to initiate third stage of Phase I/II study combining its molecule AB8939 with venetoclax for the treatment of AML (GlobeNewswire EN)
	PRESS RELEASE...

24.07.25 - 08:00	AB Science has received approval from several European countries to initiate the confirmatory phase 3 study of masitinib in ALS (GlobeNewswire EN)
	PRESS RELEASE...

08.07.25 - 08:06	AB Science announces the successful completion of a EUR 1.925 million private placement (GlobeNewswire EN)
	PRESS RELEASE...

04.07.25 - 08:48	FDA And EMA Approve AB Science′s Phase 3 Masitinib Trial In MCRPC (AFX)
	PARIS (dpa-AFX) - AB Science (ABSCF.PK) announced FDA and EMA authorization of a confirmatory Phase 3 trial of masitinib in metastatic castrate-resistant prostate cancer, using a harmonized protoc......

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Nahe bei Hofe, nahe bei der Hölle. - Sprichwort Deutschland

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram